251 related articles for article (PubMed ID: 18335793)
21. The clinical aspects of non-alcoholic fatty liver disease.
Björnsson E
Minerva Gastroenterol Dietol; 2008 Mar; 54(1):7-18. PubMed ID: 18299664
[TBL] [Abstract][Full Text] [Related]
22. Adiponectin inhibits steatotic CD95/Fas up-regulation by hepatocytes: therapeutic implications for hepatitis C.
Wedemeyer I; Bechmann LP; Odenthal M; Jochum C; Marquitan G; Drebber U; Gerken G; Gieseler RK; Dienes HP; Canbay A
J Hepatol; 2009 Jan; 50(1):140-9. PubMed ID: 19019483
[TBL] [Abstract][Full Text] [Related]
23. Definition and natural history of metabolic steatosis: histology and cellular aspects.
Paradis V; Bedossa P
Diabetes Metab; 2008 Dec; 34(6 Pt 2):638-42. PubMed ID: 19195624
[TBL] [Abstract][Full Text] [Related]
24. Histologic abnormalities are common in protocol liver allograft biopsies from patients with normal liver function tests.
Abraham SC; Poterucha JJ; Rosen CB; Demetris AJ; Krasinskas AM
Am J Surg Pathol; 2008 Jul; 32(7):965-73. PubMed ID: 18460980
[TBL] [Abstract][Full Text] [Related]
25. Pathologic assessment of non-alcoholic fatty liver disease.
Bondini S; Kleiner DE; Goodman ZD; Gramlich T; Younossi ZM
Clin Liver Dis; 2007 Feb; 11(1):17-23, vii. PubMed ID: 17544969
[TBL] [Abstract][Full Text] [Related]
26. Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis.
Wieckowska A; Papouchado BG; Li Z; Lopez R; Zein NN; Feldstein AE
Am J Gastroenterol; 2008 Jun; 103(6):1372-9. PubMed ID: 18510618
[TBL] [Abstract][Full Text] [Related]
27. [Fatty liver assessed by histologic examination in patients with hyperlipoproteinemia].
Tacikowski T; Milewski B; Dzieniszewski J; Walewska-Zielecka B
Wiad Lek; 1994 Oct; 47(19-20):731-7. PubMed ID: 7483618
[TBL] [Abstract][Full Text] [Related]
28. Definition and natural history of metabolic steatosis: clinical aspects of NAFLD, NASH and cirrhosis.
Serfaty L; Lemoine M
Diabetes Metab; 2008 Dec; 34(6 Pt 2):634-7. PubMed ID: 19195623
[TBL] [Abstract][Full Text] [Related]
29. Diagnostic evaluation of nonalcoholic fatty liver disease.
Adams LA; Talwalkar JA
J Clin Gastroenterol; 2006 Mar; 40 Suppl 1():S34-8. PubMed ID: 16540765
[TBL] [Abstract][Full Text] [Related]
30. Metformin use in children with nonalcoholic fatty liver disease: an open-label, 24-month, observational pilot study.
Nobili V; Manco M; Ciampalini P; Alisi A; Devito R; Bugianesi E; Marcellini M; Marchesini G
Clin Ther; 2008 Jun; 30(6):1168-76. PubMed ID: 18640473
[TBL] [Abstract][Full Text] [Related]
31. ERp57 is up-regulated in free fatty acids-induced steatotic L-02 cells and human nonalcoholic fatty livers.
Wang H; Chan PK; Pan SY; Kwon KH; Ye Y; Chu JH; Fong WF; Tsui WM; Yu ZL
J Cell Biochem; 2010 Aug; 110(6):1447-56. PubMed ID: 20506389
[TBL] [Abstract][Full Text] [Related]
32. [Hepatopathy of the drug addict. Morphological data and incidence of serological markers of hepatitis B virus in 65 patients].
Gottardi E; Di Marco G
Minerva Med; 1984 Nov; 75(45-46):2733-9. PubMed ID: 6521944
[TBL] [Abstract][Full Text] [Related]
33. Liver steatosis quantification using magnetic resonance imaging: a prospective comparative study with liver biopsy.
Mennesson N; Dumortier J; Hervieu V; Milot L; Guillaud O; Scoazec JY; Pilleul F
J Comput Assist Tomogr; 2009; 33(5):672-7. PubMed ID: 19820490
[TBL] [Abstract][Full Text] [Related]
34. The clinical associations with hepatic steatosis: a retrospective study.
Samarasinghe D; Tasman-Jones C
N Z Med J; 1992 Feb; 105(928):57-8. PubMed ID: 1542474
[TBL] [Abstract][Full Text] [Related]
35. Hepatic histopathology of patients with morbid obesity submitted to gastric bypass.
Lima ML; Mourão SC; Diniz MT; Leite VH
Obes Surg; 2005 May; 15(5):661-9. PubMed ID: 15946458
[TBL] [Abstract][Full Text] [Related]
36. Metabolic disturbances in non-alcoholic fatty liver disease.
Byrne CD; Olufadi R; Bruce KD; Cagampang FR; Ahmed MH
Clin Sci (Lond); 2009 Apr; 116(7):539-64. PubMed ID: 19243311
[TBL] [Abstract][Full Text] [Related]
37. Non-alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis and treatment considerations.
Preiss D; Sattar N
Clin Sci (Lond); 2008 Sep; 115(5):141-50. PubMed ID: 18662168
[TBL] [Abstract][Full Text] [Related]
38. A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease.
Fernández-Miranda C; Pérez-Carreras M; Colina F; López-Alonso G; Vargas C; Solís-Herruzo JA
Dig Liver Dis; 2008 Mar; 40(3):200-5. PubMed ID: 18261709
[TBL] [Abstract][Full Text] [Related]
39. Impact of donor graft steatosis on overall outcome and viral recurrence after liver transplantation for hepatitis C virus cirrhosis.
Briceño J; Ciria R; Pleguezuelo M; de la Mata M; Muntané J; Naranjo A; Sánchez-Hidalgo J; Marchal T; Rufián S; López-Cillero P
Liver Transpl; 2009 Jan; 15(1):37-48. PubMed ID: 19109846
[TBL] [Abstract][Full Text] [Related]
40. Liver enzymes and histology in obese patients with obstructive sleep apnea.
Kallwitz ER; Herdegen J; Madura J; Jakate S; Cotler SJ
J Clin Gastroenterol; 2007; 41(10):918-21. PubMed ID: 18090161
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
